Connect with us

Featured

Mullen Automotive, Inc (NASDAQ: MULN): Investor Interest Continues to Surge, But Challenges Persist

Published

on

Mullen Automotive, Inc. (NASDAQ: MULN) has been experiencing significant investor interest in recent months, but its share price has yet to reflect positive fluctuations. The company is actively making headlines and expanding rapidly across various EV verticals globally. Despite announcing a $25 million stock buyback program, MULN’s valuation has not appreciated considerably, remaining at around $100 million market capitalization at time of writing. 

While Mullen’s management team asserts that they are undervalued, their stock price hovers at a meager ~$0.15 per share, falling below Nasdaq’s minimum bid compliance. With a cash position of approximately $235 million, the company shows promise, but further research is needed to understand potential obstacles hindering their growth. Let’s delve into a condensed overview of their news flow to grasp the extent of their growth throughout July and the tail end of June.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

July 18th, 2023

A company MULN acquired a majority interest in, called “Bollinger Motors” launched its “design validation” pilot builds for the B4 all-electric Class 4 chassis cabs, aimed at testing and demonstration purposes. The pilot vehicles are being manufactured in collaboration with Roush Industries, Inc. in Livonia, Michigan. The company expects to roll out the first five completed chassis cabs this summer, followed by over 15 vehicles by the end of Q3 2023. The B4, designed with extensive experience in all-electric truck development, offers limitless upfit options for fleet customers and will be showcased at a demonstration event in September. Additionally, the B4 will qualify for a federal purchasing incentive, providing up to 30% of the vehicle’s cost, capped at $40,000, with deliveries set to begin in July 2024.

https://twitter.com/NashMadeit_126/status/1681415557222940696?s=20

July 17th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) has received a 30-unit order for its Mullen-GO™ Commercial Urban Delivery EV from Newgate Motor Group, marking the first sale of Mullen vehicles in Europe. Newgate, a respected dealership group based in Ireland, will handle marketing, sales, distribution, and servicing for the Mullen-GO in Ireland and the United Kingdom. The Mullen-GO, designed for quick deliveries in European cities, is fully certified and ready for sale in initial markets such as the U.K., Germany, Spain, France, and Ireland. Newgate Motor Group, with over 40 years of experience, represents reputable brands and offers top-notch service at its facility in Navan.

July 16th, 2023

Mullen Automotive (NASDAQ: MULN), initiates the transfer of its Class 1 EV cargo van vehicles from its Indiana plant to its Mississippi plant for final assembly. With over 350 vehicles already transferred and another 300 scheduled for transfer this year, the Tunica plant is nearing the production start and deliveries of Class 1 and Class 3 vehicles. Mullen Automotive’s CEO and chairman, David Michery, expressed excitement about delivering vehicles to customers starting in August 2023, anticipating continued revenue growth throughout the last six months of the year. The Southern California-based automotive company is focused on developing the next generation of electric vehicles, including the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen commercial Class 13 EVs, and Bollinger Motors, featuring electric SUV trucks and Class 46 commercial offerings.

https://twitter.com/CrozzTrade/status/1680956372001718274?s=20

July 13th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) launches an EV pilot program in collaboration with New York Power Authority (NYPA). Commencing on July 6, 2023, NYPA is conducting tests on Mullen’s all-electric Campus Delivery Utility Vehicle, the EV Cargo Van, at its upstate New York location. As a leading power generation and transmission company committed to clean energy in New York, NYPA’s 2030 Vision aims for a thriving, resilient state powered by clean energy. Mullen’s Chief Commercial Officer, John Schwegman, expressed excitement about partnering with NYPA to work towards eliminating carbon emissions in New York, emphasizing the significance of sustainable initiatives in various states. Mullen’s CEO and Chairman, David Michery, echoed the excitement about entering the utility provider market with their EVs, specifically noting the suitability of the EV cargo van for closed workplace campus scenarios. The Mullen CAMPUS, designed for low-speed, closed campus use, is a highly efficient electric van aligned with NYPA’s efforts towards sustainability. As the largest state public power organization in the nation, NYPA operates multiple generating facilities and transmission lines, with over 80% of its electricity produced from clean renewable hydropower. NYPA funds its operations through bond sales and electricity revenues.

July 11th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) introduces PowerUP, its new mobile EV charging truck capable of providing both level 2 and level 3 DC fast charging to electric vehicles in scenarios where power is limited or unavailable, such as roadside assistance and emergency response situations. The PowerUP will be featured on Mullen’s upcoming 2023 “Strikingly Different” EV Tour, providing fast charging capabilities to Mullen’s EVs during the tour. The mobile charging truck, based on a Class 5 truck platform, offers up to 150kW of continuous power generation, equipped with two level 3 DC fast chargers and four level 2 chargers. Mullen plans to offer different configurations of the PowerUP for immediate sale via advance order, making it available for commercial applications and emergency teams. The EV tour, starting in August 2023, will cover various locations on the East Coast, Midwest, Northwest, and West Coast, showcasing Mullen’s lineup of electric vehicles, including the ultra-high-performance Mullen FIVE RS with a top speed of over 200 mph and acceleration from 0-60 mph in just 1.95 seconds.

https://twitter.com/Sam1am1911/status/1679476765155282950?s=20

July 5th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) enlists the services of Christian Attar, also known as Christian Levine Law Group, in partnership with Warshaw, Burstein, LLP, to address and combat potential illegal naked short selling activities targeting the company’s common stock. In response to reports received from ShareIntel indicating possible market manipulation schemes, Mullen intends to investigate and expose any wrongdoing involved. Christian Attar and Warshaw Burstein have a track record of successfully prosecuting and securing substantial damages against broker-dealers, market-makers, hedge funds, and asset-based lenders engaged in such market manipulation practices. Mullen’s CEO and Chairman, David Michery, emphasizes their active efforts in investigating naked short selling and their determination to take appropriate legal action against market manipulators employing illegal tactics like naked short selling and spoofing. Christian Attar operates internationally and domestically, with its headquarters located in Houston, Texas, specializing in various civil litigation cases, including shareholder disputes, partnership disputes, and stock fraud.

June 29th, 2023

Mullen Automotive, Inc. (NASDAQ: MULN) achieves a notable milestone with the sale of 22 EV cargo vans to the Randy Marion Automotive Group, resulting in a recorded revenue of $308,000 for the quarter ending June 30, 2023. All vehicles are scheduled for shipment, with the first batch departing on June 29, 2023, from Mullen’s assembly plant in Tunica, Mississippi, to the Randy Marion Automotive Group in North Carolina, the authorized distributor of Mullen’s commercial EVs in the U.S. The company is also actively pursuing six Campus EV Pilot Programs in various industries, with further details expected in future announcements. The Mullen commercial team has been engaging in national events, showcasing Class 1 and Class 3 vehicles, and plans to present its commercial vehicle lineup during the 2023 “Strikingly Different” U.S. tour starting in August 2023. Mullen’s CEO and Chairman, David Michery, regards these shipments as a significant achievement, marking the company’s first recorded revenue on the financial statement, which will be reflected in the June 30, 2023, 10-Q report.

Insights from InvestorPlace: A Concise Overview

InvestorPlace wrote a bearish article on MULN, here’s the consolidated version: Mullen Automotive’s (NASDAQ: MULN) stock has faced a significant decline after its removal from the Russell 2000 Index due to failure to meet FTSE Russell’s price requirements. This exclusion from the index may result in selling pressure on MULN shares, despite the company having a substantial cash reserve of over $235 million. Mullen’s market capitalization remains low at around $30 million, leading to concerns about dilution as the company recently announced a potential resale of up to 2.33 billion shares, further increasing the number of outstanding shares. The company implemented a reverse stock split to meet Nasdaq’s listing requirements, but its stock price has continued to fall, putting it at risk of delisting from the exchange and will likely have to do another reverse stock split in the near future. Mullen’s attempts to integrate artificial intelligence technology into its vehicles have not generated substantial market enthusiasm, and its optimistic outlook amid challenging financial circumstances remains unconvincing. As a result, it is advised against holding MULN stock in 2023.

Conclusion:

Extensive research across multiple sources has unveiled a wide array of opinions regarding $MULN’s trajectory in the upcoming years. While the company’s management team perceives it as severely undervalued, a critical examination of their financial standing reveals a lack of profitability and no recorded revenue to date. Nevertheless, $MULN may stand at a crucial turning point, as they embark on commercializing several products, potentially leading to revenue generation. Yet, YahooFinance’s data highlights a staggering net income loss of approximately $739 million from operating activities, indicating that positive fundamentals may remain distant in the foreseeable future.

We will update you on MULN when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by paulbr75 from Pixabay

 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

IceCure Medical’s (NASDAQ: ICCM) ProSense: A 96.8% Success Rate Revolutionizing Breast Cancer Treatment

Published

on

On October 2nd, 2023, IceCure Medical (NASDAQ: ICCM) shares surged by over 50% following exciting news presented at a major medical event, the European Society of Breast Imaging. Their cutting-edge ProSense® System, designed for minimally invasive cryoablation, is marketed and sold worldwide for its cleared indications in the U.S., Europe, and China. More recently they gained approvals in India, and Brazil and have additional distribution through MC Medical to continue expanding in Europe. More importantly, the latest independent study confirms that the technology is a safe & effective outpatient procedure for breast cancer, with 96.8% success rate.

More Background:

Their system has the potential to revolutionize cancer treatment not only for breast cancer, but also for kidney, bone, and lung cancers. To date, the system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

During the event, Dr. Lucía Graña-López, a radiologist specializing in breast and women’s imaging, led an independent study. The study explored cryoablation as a viable alternative to surgery for early-stage breast cancer in patients who preferred a non-surgical route. The results were promising, suggesting that cryoablation could be a successful treatment option, particularly for patients hesitant about traditional surgery.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Clinical Study:

The study involved 31 patients with early-stage breast cancer who opted out of surgery, and the outcomes showed that cryoablation was well-tolerated with no major complications. This alternative approach could potentially be a game-changer, especially for breast cancer, which is one of the most prevalent cancers globally. Many patients, particularly older individuals, are seeking less invasive alternatives to surgery, making cryoablation an appealing option.

Dr. Graña-López envisions cryoablation becoming a significant alternative to surgery, particularly for early-stage breast cancer in post-menopausal women. Moreover she believes this technology could reshape how we approach treatment in other indications, particularly for kidney, lung, and thyroid gland cancers.

These results from this independent study are are in line with the ongoing ICE3 study, the largest of its kind in the U.S., set to conclude in early 2024.

We will update you on ICCM when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by marijana1 from Pixabay

Continue Reading

Featured

T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Published

on

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.

Conclusion:

T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay

 

Continue Reading

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.